- Company
- Guidelines for new obesity drugs must be established
- by Moon, sung-ho Jul 26, 2024 05:46am
- Obesity is projected to impact around 2 billion individuals by 2035. Including overweight, about 4 billion individuals will be affected by obesity, making it a significant global healthcare issue. Following this trend, pharmaceutical and biotech industry is focusing on developing next-generation treatments for obesity. Glucagon-like peptid
- Company
- Antibiotic prescriptions had surged with the pandemic
- by Kim, Jin-Gu Jul 25, 2024 05:51am
- The amount of outpatient antibiotic prescriptions in Korea had changed dramatically during the COVID-19 pandemic. In 2020 and 2021, early stages of the pandemic, antibiotic prescriptions dropped sharply but then surged in 2022. In contrast, the proportion of cephalosporin and quinolone antibiotic prescriptions, which are more powerful than ot
- Company
- Meningitis B vaccine Bexsero is released in Korea
- by Moon, sung-ho Jul 25, 2024 05:51am
- Competition in the 'meningococcal' vaccine market, which is mainly vaccinated in pediatric clinics, has recently been reignited. Although its domestic market is worth less than KRW 10 billion, the emergence of next-generation vaccines is expected to spark new competition among multinational pharmaceutical companies. This is because GSK
- Company
- 'Padcev+Keytruda' combination therapy is set to land in KOR
- by Eo, Yun-Ho Jul 25, 2024 05:51am
- The combination therapy of 'Padcev+Keytruda,' which is expected to bring a paradigm shift to bladder cancer treatment, will soon land in South Korea. The Ministry of Food and Drug Safety (MFDS) is reviewing the expansion of indication for Astellas Korea's Padcev (enfortumab), an antibody-drug conjugate (ADC), in combination with Keytruda
- Company
- Samsung Bioepis’ Soliris biosimilar is approved in the U.S.
- by Chon, Seung-Hyun Jul 24, 2024 05:51am
- [데일리팜=천승현 기자] 삼성바이오에피스는 미국 식품의약품국(FDA)으로부터 희귀질환치료제 ‘에피스클리’의 품목허가를 획득했다고 23일 밝혔다. 에피스클리는 미국 알렉시온이 개발한 솔리리스의 바이오시밀러 제품이다. 에피스클리는 발작성 야간 혈색소뇨증, 비정형 용혈성 요독 증후군의 치료제로 FDA 승인을 받았다. 삼성바이오에피스는 2019년 7월부
- Company
- Reimb applied for new HIV drug 'Vocabria+Rekambys'
- by Eo, Yun-Ho Jul 24, 2024 05:50am
- Long-acting HIV treatment 'Vocabria+Rekambys' combination therapy aims to be listed for insurance reimbursement after receiving approval in South Korea two years ago. Industry sources said that GSK Korea and Janssen Korea have applied for reimbursement for the combination therapy of Vocabria (cabotegravir) and Rekambys (rilpivirine), whic
- Company
- Will 'Zejula' be reimbursed for HRD-positive ovarian cancer?
- by Eo, Yun-Ho Jul 23, 2024 05:48am
- Whether the insurance reimbursement criteria for 'Zejula,' a PARP inhibitor, will include 'HRD-positive' is gaining attention. Sources said that Takeda Pharmaceuticals Korea is negotiating the price with the National Health Insurance Service (NHIS) for the Poly ADP-ribose Polymerase (PARP) inhibitor, Zejula, which is used to treat ovarian
- Company
- Opdivo approved as 1st-line Tx for urothelial cell carcinoma
- by Hwang, Byung-woo Jul 23, 2024 05:48am
- Ono Pharma Korea and BMS Korea announced on the 22nd that Opdivo (nivolumab) has been additionally approved by the Ministry of Food and Drug Safety as a first-line treatment for urothelial cell carcinoma (UCC). The new indication is for the first-line treatment of unresectable or metastatic urothelial cell carcinoma in combination with ci
- Company
- "Trodelvy gives new hope for triple-negative breast cancer"
- by Son, Hyung-Min Jul 23, 2024 05:48am
- Triple-negative breast cancer refers to a breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is a rare cancer that accounts for about 12-15% of all breast cancer. This cancer tends to be aggressive and has a high risk of metastasis and recurrence, leading
- Company
- Eisai reports degrowth for 3 consecutive years
- by Hwang, Byung-woo Jul 23, 2024 05:47am
- Eisai Korea has recorded a decline in sales of its flagship products, including its anti-cancer drug Lenvima (lenvatinib), for 3 consecutive years since 2020. The company has not seen a clear rebound since experiencing a significant drop in sales in 2022. The company’s JAK inhibitor Jyseleca (filgotinib), which was listed for reimbursement
